UNSPSC 51263012: Terazosin hydrochloride dihydrate

This classification denotes an alpha-adrenergic blocking agent with the molecular formula C19H25N5O4.ClH.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D32S14F082, chemically known as 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(tetrahydro-2-furoyl)piperazine but more generally known as terazosin hydrochloride dihydrate, which bears US NIH Compound Identifier 5401. European Medicines Agency schedules Terazosin hydrochloride dihydrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04722MIG.

Most nations, for tariff and trade purposes, schedule terazosin hydrochloride dihydrate under HS 29349990. SMILES: COC1CC2C(CC1OC)NC(NC2N)N3CCN(CC3)C(=O)C4CCCO4.O.O.CL.

UNSPSC 51263012 Terazosin hydrochloride dihydrate is a Commodity code that does not align with recent state and local procurement activity. The code nominally describes a specific pharmaceutical compound used to treat hypertension and benign prostatic hyperplasia, but the posted opportunities tagged under this code involve naloxone procurement and therapeutic pharmacy initiative planning—neither of which relates to terazosin hydrochloride dihydrate. The mismatch suggests either a classification error in the opportunities or minimal legitimate procurement activity under this Commodity code at the state and local level.

The source contains no recent opportunities actually soliciting terazosin hydrochloride dihydrate itself. State and local health agencies and purchasing offices may acquire this drug through standing pharmacy benefit arrangements, group purchasing organizations, or state formulary programs, but no active RFP, RFQ, IFB, or ITB notices for this specific pharmaceutical compound appear in current records. The code shows little relevant recent activity and warrants a watch status rather than active pursuit unless supplementary sourcing data reveals hidden procurement volume through cooperative purchasing vehicles or state pharmaceutical contracts not surfaced in standard notice channels.